Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin

Kelly E. Dooley, Anne F. Luetkemeyer, Jeong Gun Park, Reena Allen, Yoninah Cramer, Stephen Murray, Deborah Sutherland, Francesca Aweeka, Susan L. Koletar, Florence Marzan, Jing Bao, Rada Savic, David W. Haas, Liz Barr, Erica Egizi, Laura Hovind, Jennifer Janik, Patricia Lizak, Carl Mendel, Thucuma Size

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin'. Together they form a unique fingerprint.

Medicine & Life Sciences